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Abstract: Cell Signaling pathways form an integral part of our existence that allows the cells to comprehend a 
stimulus and respond back. Such reactions to external cues from the environment are required and are essential to 
regulate the normal functioning of our body. Abnormalities in the system arise when there are errors developed in 
these signals, resulting in a complication or a disease. Presently, respiratory diseases contribute to being the third 
leading cause of morbidity worldwide. According to the current statistics, over 339 million people are asthmatic, 
65 million are suffering from COPD, 2.3 million are lung cancer patients and 10 million are tuberculosis patients. 
This toll of statistics with chronic respiratory diseases leaves a heavy burden on society and the nation's annual 
health expenditure. Hence, a better understanding of the processes governing these cellular pathways will enable 
us to treat and manage these deadly respiratory diseases effectively. Moreover, it is important to comprehend the 
synergy and interplay of the cellular signaling pathways in respiratory diseases, which will enable us to explore 
and develop suitable strategies for targeted drug delivery. This review, in particular, focuses on the major respira-
tory diseases and further provides an in-depth discussion on the various cell signaling pathways that are involved 
in the pathophysiology of respiratory diseases. Moreover, the review also analyses the defining concepts about 
advanced nano-drug delivery systems involving various nanocarriers and propose newer prospects to minimize 
the current challenges faced by researchers and formulation scientists. 
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1. INTRODUCTION 
 Cell signaling or communication among the cells is one of the 
key factors in understanding both cellular mechanisms and system 
functioning [1–6]. There are various cell signaling pathways that 
are involved in a myriad of specific mechanisms in the body, rang-
ing from an antigen triggered antibody response to targeted cells 
responding to particular hormones. The cells in the body are con-
stantly connected to each other in order to maintain the coordina-
tion and regulated response throughout [7, 8]. However, any dys-
functionality in such a cellular signaling process leads to abnormal-
ity or disease. In most cases, cellular interaction involves the bind-
ing of a targeted molecule to a specific receptor that is present on 
the plasma membrane. This triggers a cascade of reactions to regu-
late the external stimuli and thereby influence cellular behavior [9]. 
Cytokine receptors, G protein-coupled receptors (GPCRs), Recep-
tor tyrosine kinase (RTKs) and Transforming growth factor- beta 
(TGF-β) is the common receptor involved in cell signaling [10]. 
These receptors involved in cell signaling, generally perceive the 
on-going information over the cell surface and communicate it to 
the nearby cells. Standard cascade signaling reactions are usually 
triggered within the nucleus, which further regulates the transcrip-
tion factors and amends regulation of genes as well as cellular re-
sponses [9]. 
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 These cell signaling pathways are the primary regulators of the 
normal functioning of the cellular system. Hence, any changes in 
these cell signaling pathways may result in aberrations in the body 
[11–14]. Approximately, 8.3% of the global population suffers from 
chronic respiratory diseases (CRDs), due to the aberrant functioning 
of the respiratory system [15]. These CRDs, namely, asthma, 
Chronic Obstructive Pulmonary Disease (COPD), tuberculosis (TB) 
and lung cancer occur because of i) causative environmental fac-
tors, ii) microbial infections, iii) genetic make-up and iv) the life-
style of the individual [16–19]. CRDs demonstrate the involvement 
of a chemical entity, foreign agent, interleukins, oxidative agent or 
proteins, which are directly or indirectly associated with these cell-
signaling pathways, and therefore, can serve as the active target for 
treating these CRDs. Targeting cytokines for CRDs can be a poten-
tial therapeutic intervention via blocking antibodies or therapeutic 
proteins. An emerging role of IL-4, IL-5 and IL-13 was found as 
anti-cytokine therapies for asthma [20]. Anti-IL-5 antibody has 
been found to be effective in reducing eosinophil numbers in blood 
and sputum, however, it was found to be substantially less effective 
at reducing eosinophil numbers in the lung and had a modest impact 
on lung function [21]. A recent study showed the role of neuroim-
mune semaphorin 4A in downregulating asthma severity by regula-
tion of IL-13. Several therapeutics targeting the tumour necrosis 
factor (TNF)-α pathway have been developed and used in clinical 
trials. Therapeutics such as mouse/human IgG1 antibody against 
TNF-β, infliximab have been found to be effective in asthma com-
pared to COPD [22].  
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 The role of NLRP3, caspase-1 and IL-1β responses has been 
found to be elevated in the lungs of Chlamydia infection-induced 
experimental severe steroid-resistant asthma [23] and the sputum 
NLRP3 and IL-1β expression correlate to key clinical parameters of 
human severe steroid-resistant asthma, including increased numbers 
of neutrophils in the airways, and reduced lung function. The func-
tional roles and potential for therapeutic targeting of NLRP3, 
caspase-1 and IL-1β in experimental severe steroid resistant asthma 
by intranasally administering MCC950 (a potent and highly selec-
tive NLRP3 inflammasome inhibitor, ac-YVAD-cho (a selective 
caspase-1 inhibitor) or neutralising anti-IL-1β monoclonal antibody 
during Chlamydia and Haemophilus infection-induced severe ster-
oid-resistant asthma. The elevated lung IL-1β response was sup-
pressed by treatments, and this was associated with the suppression 
of steroid-resistant neutrophilic airway inflammation and airways 
hyper-responsiveness. Therefore, targeting the exaggerated NLRP3 
inflammasome response component in severe steroid-resistant 
asthma is a novel therapeutic approach and suggests the clinical 
preference as it allows IL-1β processing through other mechanisms 
for protection against infections [24]. 
 Furthermore, several known inflammatory target proteins in-
cluding matrix metalloproteinase-9 (MMP-9), intercellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-
1), cyclooxygenase-2 (COX-2), and cytosolic phospholipase 
A2 (cPLA2) have been associated with airway and lung inflamma-
tion in response to different stimuli [25]. The environmental insults 
can reach the lung through airways or pulmonary and systemic 
circulations. The responses by circulating and resident cells is regu-
lated by different inflammatory signaling pathways, such as Src 
family kinases (SFKs), protein kinase C (PKC), nicotinamide ade-
nine dinucleotide phosphate (NADPH)/reactive oxygen species 
(ROS), PI3K/Akt, MAPKs, nuclear factor-kappa B (NF-κB), acti-
vator protein-1 (AP-1) and activator of transcription proteins (JAK-
STAT) [26-28]. These signaling pathways regulate inflammatory 
signaling pathways and target proteins involved in airway and lung 
inflammation [29, 30]. 
 Current traditional approaches employed in the treatment and 
management of these CRDs have become ineffective, as they were 
originally designed to only adhere and function on the general site 
[31, 32]. Extensive research on how these respiratory diseases de-
velop under different pathological conditions, along with the vari-
ous factors that come into play, has uncovered the variability 
among these diseases and has assisted scientists and researchers in 
comprehending the role of cell signaling pathways [29, 33, 34]. 
This review focuses on understanding the function of cell signaling 
pathways and their synergy with CRDs. Additionally, it will also 
speculate on various nano-drug delivery systems and nanocarriers 
currently employed and attempts to propose newer prospects for 
minimizing the challenges in the near future. 
2. GLOBAL PREVALENCE OF MAJOR RESPIRATORY 
DISEASES 
 Globally, CRDs are becoming one of the leading causes of 
morbidity and mortality. Additionally, the rate of CRDs is exponen-
tially increasing and advancing in all socioeconomic classes, as 
well as regions [35]. According to the World Health Report, the 
disability, morbidity, and mortality attributed to these CRDs ac-
count for up to 8.3% of the global burden. Moreover, most of the 
deaths caused by these CRDs occur in developing countries [15, 
36–38]. The four most prevailing chronic respiratory diseases are 
pictorially illustrated in Fig.1., and their key features are discussed 
below:    
 Asthma is a chronic inflammatory disease of the upper airways, 
characterised by airway hyper-responsiveness (AHR), airflow ob-
struction and eosinophilic infiltration [39]. Common symptoms of 
this disease range from a persistent cough, dyspnea to wheezing. 
Allergy is reported to be one of the major causes of asthma. Here, 
the bronchioles of the upper airways get inflamed, as well as nar-
rowed because of edema. It is further associated with remodeling of 
the smooth muscles and mucus production [40].  According to the 
consensus of the Global Burden of Disease-2016 (GBD), there are 
around 339 million people worldwide, who are suffering from 
asthma, which is higher by 3.6% from the report published in 2006 
[41, 42]. Globally, asthma ranks as the 23rd leading cause of mortal-
ity [43]. 
 COPD is a progressive inflammatory lung disease character-
ized by persistent airflow limitation, caused primarily by inhaling 
smoke or noxious particles. The primary symptoms of COPD are 
recurrent incidences of dyspnea, wheezing and cough (with or 
without mucus) [44]. COPD causes enlargement of air spaces in the 
bronchioles, disrupting the lung tissues, and eventually resulting in 
difficulty to breathe. As per the 2016 statistics, around 328 million 
people suffer from COPD worldwide [45]. It has been reported that 
COPD accounted for 3.17 million deaths in the year 2015 alone, of 
which, more than 90% of people belong to developing countries. 
Globally, COPD holds the 10th position as the leading cause of 
mortality [46].    
 Lung Cancer, a chronic respiratory disease, is caused by a 
mutation in the protective gene or due to DNA damage resulting 
from persistent smoking or indirect inhalation [47]. Other causes 
may be air pollution, workplace exposure to certain chemicals such 
as asbestos, nickel, chromium, radioactive gases like radon etc. 
[48–51]. The hallmark of lung cancer, like most other cancers, is 
characterized by abnormal and uncontrolled cell division, which 
invades nearby tissues, primarily in the lining of air passages [52]. 
On the basis of histology, they are further classified as non-small 
cell lung cancer (NSCLC) and small cell lung cancer (SCLC). 
Moreover, NSCLC is further sub-classified into three sub-groups, 
namely, Adenocarcinoma (AD), Squamous-cell cancer (SQ) and 
Large-cell cancer (LC) [53]. The symptoms observed in patients 
suffering from lung cancer involves loss of appetite, chest pain, 
cough, compromised immune system, wheezing, and heavy sputum 
production [54]. As per the available consensus, lung cancer is one 
of the leading causes of death and accounts for around 1.4 million 
deaths every year. According to the WHO (2018), there have been 
1.76 million deaths worldwide due to lung cancer. The highest 
prevalence of this disease is recorded in developing countries [55]. 
Globally, lung cancer holds the 5th position as a leading cause of 
mortality [42].          
 Tuberculosis (TB) is a chronic infectious disease caused by the 
bacterium, Mycobacterium tuberculosis. The bacterium usually 
infects the lungs first, then slowly, they affect the other organs like 
genito-urinary tract, lymph nodes and the skeletal system [56]. 
Moreover, it spreads to other people through cough, sneeze or 
physical interaction. This infectious disease shows symptoms like 
cough with sputum that contains or stained with blood, fatigue, 
fever, loss of weight and night sweats [57]. Globally, TB has been 
accounted for over 1.5 million deaths in 2018 alone, and about 10 
million people are still prone to TB. Moreover, the burden of TB is 
mostly in developing countries. Multi-Drug Resistant TB has 
evolved as a major threat to public health [58]. Globally, TB holds 
the 9th position as the leading cause of mortality [59–61].  
 Interstitial Lung Disease (ILD) is a wide group of pulmonary 
diseases that include more than 100 disorders which cause scarring 
and fibrosis of the lung [62]. The characteristic manifestations of 
ILDs are variable and include respiratory symptoms (cough, dysp-
nea), reduced pulmonary capacity, chest x-ray abnormalities and 
pathological fibrosis. ILDs can be categorised into individual disor-
ders according to some of those specific clinical, radiological and 
histopathological characteristics [63]. For example, granulomatous 
inflammation is characteristic of sarcoidosis whereas pulmonary 
fibrosis and lung distortion are unique to idiopathic pulmonary 
fibrosis (IPF) [64]. The most common ILD is IPF, with an estima-
tion of approximately 3 million people suffering from IPF world-
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wide and 130 000 persons in the United States [65]. ILDs are idio-
pathic disorders in most cases, meaning the cause of lung damage 
and resulting fibrosis is unclear [62].  
3. TARGETED CELL SIGNALING PATHWAYS INVOLVED 
IN RESPIRATORY DISEASES  
 There are numerous cell signaling pathways involved in regu-
lating the normal functioning of the cell. Most of these cell signal-
ing pathways are activated by external signals that transfer informa-
tion within the cell from its surface to the effector site [66–68]. The 
focus of this review revolves around the cell signaling pathways 
that are primarily involved in respiratory diseases. The major cell 
signaling pathways (Fig. 2) are summarized below: 
4. AKt/PKB/PI3K SIGNALING PATHWAY 
 Akt/PKB/PI3K signaling pathway is an intracellular signaling 
pathway having a vital role in regulating the various cellular func-
tions like development, growth, metabolism, proliferation, protein 
synthesis, survival and transcription [69]. The Akt/PKB/PI3K gets 
activated either by growth factors, hormones or nutrients [70]. The 
reaction cascade is triggered by external stimuli on the interaction 
with any of the receptors, namely, B and T cell receptors, cytokine 
receptors, G-protein-coupled receptors (GPCR), integrins and tyro-
sine kinase [71]. This interaction activates PI3K and triggers the 
generation of phosphatidylinositol-(3,4,5)-trisphosphates (also 
known as PIP3) via phosphorylation. After that, the synthesized 
PIP3 binds with the pleckstrin homology (PH) domain of Akt for 
facilitating its transfer to the plasma membrane [72, 73]. In the 
plasma membrane, Akt gets phosphorylated by Phosphoinositide-
dependent kinase 1 (PDK1) at Thr308, which partially activates the 
Akt. The phosphorylation of Akt at Ser473 via mTORC2 com-
pletely activates the function of the enzyme and regulates the nor-
mal functioning of the cellular processes [74, 75].      
5. JAK-STAT SIGNALING PATHWAY 
 JAK-STAT is another intracellular signaling pathway that regu-
lates and controls cellular functions like development and homeo-
stasis [76]. This pathway gets activated by the interaction of cytoki-
nes (i.e., interferons) with receptors like epidermal growth factor 
receptor (EGFR), GPCR, and platelet-derived growth factor recep-
tor (PDGFR) [77]. This interaction phosphorylates the JAKs asso-
ciated with these receptors on the cytoplasmic side. Hence, these 
phosphorylated JAKs further phosphorylates the tyrosine residues 
of the receptor to generate the docking site for Src Homology 2 
(SH2) domain of STATs [78]. These docked STATs get phosphory-
lated by JAKs associated with tyrosine residues located at the C-
terminal end. After the phosphorylation of STATs via SH2-
phosphotyrosine interaction, it dissociates itself from the receptor 
[79, 80]. Dimerized STATs are then imported into the nucleus with 
the help of importin-α (i.e., Imp- α). After these events, STATs 
attach themselves to the promoter region via the DNA-binding do-
main, which further regulates the transcription of genes essential for 
cellular processes [81].  
6. MAPK SIGNALING PATHWAY 
 The MAPK signaling pathway is associated with various differ-
ent pathways and aids in regulating several important cellular proc-
esses like apoptosis, metabolism, proliferation and transcription 
 
Fig. (1). Overview of the common chronic respiratory diseases. (A higher resolution / colour version of this figure is available in the electronic copy of the 
article). 
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[82, 83]. These different downstream processes get activated by the 
final MAPK component attached to any of the three signaling 
pathways like Extracellular-signal regulated kinase (ERK) pathway, 
c-Jun-N-terminal kinase (JNK) pathway and p38 pathway [84]. 
External stimuli activate this signaling pathway. The pathway pri-
marily acts on one of the 14 different types of MAPK kinase 
kinases (MAPKKKs). On activation, these MAPKKKs further 
phosphorylate one of the 7 types of MAPK kinases (MAPKKs). 
Sequentially, the phosphorylated MAPKKs further continue to 
phosphorylate one of the 12 MAPKs for eliciting the cellular re-
sponses [82].    
7. NF-κB SIGNALING PATHWAY 
 NF-κB signaling pathway is activated by different external 
stimuli, namely, interleukin-1 (IL-1), pathogen-associated molecu-
lar patterns (PAMPs) and tumor necrosis factor-alpha (TNF-α), 
responsible for regulating different cellular processes like apopto-
sis, inflammation and proliferation [85]. This pathway is usually 
initiated by the interaction of external stimuli with a TNF receptor. 
On activation, p50 and p65 isoforms of NF-κB form the dimer and 
recruit the signaling complex on the membrane [86]. The signaling 
complex comprises the inhibitors of NF-κB (IκB) kinase, i.e., IKKα 
and IKKβ. These IKKα and IKKβ form the dimer for phosphorylat-
ing the IκBα subunit, which later aids in retaining the p50/p65 iso-
mers within the cytoplasm [87]. Proteasome then acts on it and 
degrades the phosphorylated IκBα, liberating the homodimer of 
p50/p65 isomers. The homodimer of p50/p65 isomers is then im-
ported inside the nucleus to regulate the transcription of genes es-
sential for cellular processes [88]. 
8. ASSOCIATION OF TARGETED CELL SIGNALING 
PATHWAYS WITH MAJOR RESPIRATORY DISEASES 
 The cell signaling pathways have the key responsibility to per-
form important cellular functions. However, any change or altera-
tion in these cell signaling pathways causes a defect, which eventu-
ally leads to the development of diseases [11]. There are huge 
variations in the nature of the pathogenesis, of how each disease 
gets induced. In a few cases, pathogenic organisms also interfere 
with these cell-signaling pathways. Thus, tracing the defects in 
these cell-signaling pathways will also explain the synergism be-
tween CRDs and cell signaling pathways [89]. 
 Acute respiratory distress syndrome (ARDS) is a systemic in-
flammatory disease where lungs and other organ systems are in-
volved [90]. This causes increased inflammatory cytokines such as 
IL-1β, TNF-α, IL-6, and IL-8 in bronchoalveolar lavage fluid and 
blood [91]. Development, progression and recovery of ARDS have 
 
Fig. (2). The classical representation of major cell signaling pathways involved in chronic respiratory diseases. Here, 1- TNF receptor, 2- Integrin receptor, 3- 
PAMPs receptor, 4- EGF receptor, 5- Interleukin receptor, 6- Tyrosine kinase receptor, 7- PGF receptor, 8- Cytokine receptor, 9- GPC receptor. (A higher 
resolution / colour version of this figure is available in the electronic copy of the article). 
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been related to TLR signaling pathways. An extracellular matrix 
glycosaminoglycan, Hyaluronan is produced after tissue injury, 
which further leads to development of inflammatory response in 
ARDS via TLR2 and TLR4, and at the same time, promotes recov-
ery from ARDS [91]. TLR3 mediates hyperoxia-induced ARDS 
and TLR2 mediates hemorrhage induced ARDS [92]. Studies have 
shown the role of inflammasomes in inflammation during acute 
lung injury. NLRP3 inflammasome interacts with extracellular 
histones and leads to the development of hypoxemia-induced 
ARDS [93]. Once, ARDS results in systemic inflammation; there is 
a release of mitochondrial components, including mitochondrial 
DNA, formyl peptides in the circulation, causing cellular damage 
[94].  
 Asthma, a chronic inflammatory disease, is triggered by IL, 
which are found to be involved in cell signaling pathways like 
Akt/PKB/P13K, JAK-STAT, MAPK, and NF-κB signaling path-
ways [95]. During the pathogenesis of this disease, IL-4/13 causes 
the phosphorylation of JAK, which activates the STAT transcrip-
tion factor and elicit the expression of inflammatory mediator 
genes. Moreover, there is a production of cyclooxygenase-2 (COX-
2) and Inducible Nitric Oxide Synthase (iNOS) in the NF-κB sig-
naling pathway during pulmonary inflammation [96]. Additionally, 
the upregulation in the levels of IgE and IL-4 is also observed in the 
MAPK pathway in asthma [97]. Furthermore, miR-107 is found to 
be indirectly involved in the inflammatory response of asthma [98]. 
Association of these inflammatory proteins with asthma and their 
involvement with cell signaling pathways exhibit a wide range of 
potential therapeutic targets.  
 COPD, a progressive inflammatory lung disease, is found to 
involve known inflammatory proteins like COX-2, cytosolic phos-
pholipase A2 (cPLA2), intercellular adhesion molecule-1 (ICAM-
1), metalloproteinase-9 (MMP-9) and vascular cell adhesion mole-
cule-1 (VCAM-1) that are associated with cell signaling pathways 
[99]. An increase in the level of MMP-2/9 serves as the marker for 
COPD [100]. Protein Kinase C (PKCs) is another intermediate 
involved in CRD like COPD [101]. ROS development also triggers 
the inflammatory reaction by activating the NF-κB or Akt/PKB/ 
PI3K. PI3K plays a major role in the expression of multiple in-
flammation-related genes [102]. The synergism between these in-
flammatory proteins and cell signaling pathways portrays their 
association with COPD and allows us to better understand this 
chronic disease.  
 Lung cancer, a chronic respiratory disease, is elicited due to a 
mutation in the tyrosine kinase domain of the cell signaling path-
way [103]. Overexpression of EGFR is also found to play a critical 
role in carcinogenesis, especially in NSCLC [104]. Additionally, 
the mTOR pathway is reported to be involved in carcinogenesis. 
MAPK pathway is the major pathway that is found to play a sig-
nificant role in the pathogenesis of lung cancer [105]. The expres-
sion of MAPK phosphatase 1, as well as mutations in phosphoinosi-
tide-3-kinase and catalytic alpha polypeptide (PIK3CA), are the 
determining factors in lung cancer. Moreover, there is significant 
involvement of Akt/PKB/PI3K and NF-kB signaling pathways 
[106]. Furthermore, the expression of peroxisome proliferator-
activated receptors in lung cancer serves as a biomarker for lung 
cancer [107]. The involvement of the proteins and receptors plays a 
significant role in the onset of disease in an individual.   
 Tuberculosis, an infectious disease, triggers alterations in dif-
ferent inducers involved in cell signaling pathways like 
Akt/PKB/PI3K, JAK-STAT, MAPK and NF-κB [108, 109]. Plei-
otropic cytokine and TNF-α are the chief proinflammatory media-
tors that are involved in the establishment of TB infection [110]. 
Additionally, the interaction of M. tuberculosis receptors with the 
host pattern recognition receptors has been understood as the prin-
cipal reason to elicit the production of cytokines like CXCL2/3(C-
X-C motif chemokine ligand 2), CCL2/5 (C-C Motif Chemokine 
Ligand 2) and interleukins (IL8) [111]. The receptor-interacting 
serine/threonine-protein kinase 1 (RIPK1) has also been found to 
promote the activation of MAPKs and NF-κB signaling pathway. In 
normal conditions, RIPK1 ubiquitination via cellular inhibitor of 
apoptosis protein 1 (cIAP1) protein takes place, and it works as an 
anti-apoptosis effector. However, any alteration in the ubiquitina-
tion of RIPK1 causes apoptosis [34]. Therefore, the involvement of 
different proteins and receptors shows and highlights the role of 
these signaling pathways in the progression of diseases.  
 Idiopathic pulmonary fibrosis (IPF) results in alveolar remodel-
ling and loss of pulmonary function, further leading to respiratory 
failure and death within 5 years of diagnosis [112]. IPF pathogene-
sis comprises of fibrotic remodelling, inflammation, and loss of 
lung architecture [113]. Experimental mouse models have shown 
alveolar remodelling and fibrosis along with activation of TGF-β, 
TGF-α, and the mTOR/PI3K/AKT pathways  [114, 115]. RNA 
sequencing analysis of IPF shows the activation of Hippo/YAP 
pathway genes and inhibits the SAV1 and MST2 pathway. It also 
causes activation of mTOR/PI3K/AKT signaling, including in-
creased MLST8 and decreased phosphatase and tensin homology 
(PTEN) expression, indicating potential interactions between YAP 
and mTOR signaling pathways [116]. 
 All CRDs demonstrate the involvement of a chemical entity, 
foreign agent, interleukins, oxidative agent or proteins, which are 
directly or indirectly associated with these cell-signaling pathways, 
and therefore, can serve as the active target for treating these CRDs. 
9. NEED FOR DRUG DELIVERY APPROACHES TO TAR-
GET CELL SIGNALING PATHWAYS IN RESPIRATORY 
DISORDERS 
 Acute respiratory distress syndrome (ARDS) is characterised by 
a heterogeneous group of lung diseases along with acute lung injury 
in critically ill patients, leading to high mortality rates. A number of 
molecules are associated with the molecular pathology of ARDS. 
These include Nod-like receptors, Toll-like receptors and down-
stream signaling molecules such as NF-κB, inflammasomes, and 
effector molecules like IL-18, IL-1β, and TNF-α. Multiple targets 
have been identified and evaluated for developing potential thera-
pies for ARDS. Targeting key molecules like NF-κB suppresses 
inflammation of the lungs but has significant limitations since inhi-
bition of NF-κB is immunosuppressive and affects host immunity 
[117]. 
 Nanobiotechnology has proved to be the basis of innovative 
techniques for delivering drugs to the site of inflamed organs, in-
cluding lungs. Nanoscale drug delivery systems are capable of im-
proving the pharmacokinetics as well as pharmacodynamics of 
agents, resulting in an increased bio-distribution of therapeutic 
agents to the site of action and thus improving efficacy of the drug 
with reduced toxicity [36, 118-128]. MAPK inhibitor ARRY-
142886 and the PI3K inhibitor PX-866 is reported to regulate pul-
monary fibrosis progression, preserving vital physiological parame-
ters, in a transgenic mice model that overexpressed the ‘transform-
ing growth factor’ and developed spontaneous pulmonary fibrosis, 
[129]. Administration of the mTOR (mammalian target of rapamy-
cin) inhibitor rapamycin in this model inhibited the progression of 
pulmonary fibrosis by preventing the activation of the EGFR sig-
naling pathway [130].  
 Administration of bio-therapeutic agents systemically allows 
barely a small amount of drug to reach the targeted site, as the ma-
jor part of the drug remains distributed in tissues apart from the 
primary target site. Targeted delivery to a particular organ or tissue 
may increase the accumulation of drug at the site of action, result-
ing in improved safety and efficacy [13, 121, 122, 126, 131]. It was 
reported that targeting plasmalemma vesicle-associated protein 
(PV1), which is present on the lung endothelial cells, can enhance 
drug accumulation and thereby improve pulmonary fibrosis state. In 
a mouse model with idiopathic pulmonary fibrosis (IPF), induced 
by bleomycin, the fibrosis, as well as collagen content, were found 
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to be significantly reduced when Prostaglandin E2 (PGE2) conju-
gated αPV1 was administered, while no such effects were observed 
with a non-targeted PGE2 antibody conjugate. The results demon-
strate that PV1 targeting can be an effective mode for delivering 
therapeutics to lung tissues, and this approach can be very helpful 
in the treatment of several lung diseases [16, 132]. Considering all 
the above preclinical and translational evidences, there is an emerg-
ing need for advanced drug delivery systems, which can encapsu-
late identified biological moieties to target diseases such as ARDS, 
pulmonary fibrosis, etc. Fig. 3. 
 
 
Fig. (3). Pictorial Illustration of Different Types of Nanocarrier Based Drug 
Delivery Systems. (A higher resolution / colour version of this figure is 
available in the electronic copy of the article). 
10. LIPOSOMES 
 Liposomes are small artificial amphiphilic structures made of 
cholesterol and various phospholipids [133, 134]. The amphiphilic 
characteristics of phospholipids enable them to dissolve in both 
hydrophobic and hydrophilic drugs. Based on the nature of the 
drug, these particles can either lodge themselves in the liposome 
core membrane or in the lipid-aqueous interface [135, 136]. 
 Liposomes have been used as carriers to deliver drugs to treat 
respiratory infections caused by multi-drug resistant Pseudomonas 
aeruginosa. In one study, transport of colistin and ciprofloxacin 
liposomes across in Calu-3 cell monolayer indicated that liposomes 
can prolong the time of drug retention on the lung epithelial surface 
[137]. Several other studies have also demonstrated the capability 
of liposomes in prolonging drug retention time and increasing drug 
concentration in the desired site. Chen et al., reported that the 
transport rate of liposomal salbutamol into airway epithelial cells 
was slower than free salbutamol, and in vivo studies demonstrated 
the duration of anti-asthmatic effect of encapsulated salbutamol 
being prolonged by two times in comparison with free salbutamol 
solution [61, 138]. 
 Pandolfi et al. used liposomes containing hyaluronic acid (HA-
liposomes) for inhalation treatment of collagen tissue disease-
associated interstitial lung fibrosis (CTD-ILDs) and bronchiolitis 
obliterans syndrome (BOS). They prepared two HA-liposomes with 
different HA molecular weights (MW) and a plain liposome (LIP) 
to study the effects of HA MW on the targeting efficiency of lung 
fibrotic cells and inflammatory effectors. Results of real-time qPCR 
showed that treatment of human THP-1 cells with the above-
mentioned liposomes significantly reduced levels of pro-
inflammatory cytokines, namely, IL-1β and IL-12, while TGF-β 
was increased. Furthermore, both LIP and LIP-HA of lower MW 
increased IL-8 release, while, there was no increase in observed IL-
8 levels following the treatment with LIP-HA of higher MW [139]. 
 In another in vitro study, quercetin, a natural flavonoid, was 
encapsulated in T7 surface-functionalized liposomes (T7-QR-lip) to 
target transferrin receptors of lung tumor cells. The study indicated 
that a 2% peptide density for T7-QR-lip resulted in a significant 
inhibition in lung tumor spheroids growth. Inhibition of tumor 
growth and prolongation of lifespan after T7-QR-lip treatment 
through pulmonary administration was also confirmed with in vivo 
studies [140]. 
11. NANOSTRUCTURED LIPID CARRIERS 
 Nanostructured lipid carriers (NLCs) are the second-generation 
lipid nanoparticles prepared from a mixture of solid lipids (e.g., 
Precirol ATO 5) and spatially incompatible liquid lipids (e.g. 
Squalene) by melt-emulsification. NLCs have been explored as an 
alternative drug carrier combining the advantages of solid lipid 
nanoparticles with high encapsulation efficiency and reduced drug 
leakage [141–149] as a result of their lipophilic and bioadhesive 
properties. NLCs demonstrate increased residence in the lung and 
sustained release of the entrapped drug from the lipid matrices 
[150]. NLCs have been found suitable for the delivery of different 
drugs and siRNAs. Lipophilic drugs can be loaded into the inner 
core of NLCs. In addition, the surface of the NLCs can be modified 
with polyethylene glycol polymer for targeted drug delivery. NLCs 
containing paclitaxel and siRNA targeted to multidrug resistance 
protein 1 and B-cell lymphoma 2  mRNAs for inhalation chemo-
therapy of lung cancer demonstrated therapeutic efficacy. In the 
treatment of lung cancer with LHRH-targeted NLCs, it was demon-
strated that the NLCs predominately accumulated in the lung tumor 
tissues with a minimal concentration of the NLCs in healthy tissues 
[151]. 
 Several studies have used NLCs to treat respiratory inflamma-
tory conditions such as asthma and COPD. Montelukast is a leukot-
riene receptor antagonist used to prevent wheezing and asthma-
induced coughing. Inhalable montelukast-loaded NLCs have shown 
improved systemic bioavailability and therapeutic outcomes when 
compared to free montelukast in vivo. Rosuvastatin, which is used 
in the management of high LDL and cholesterol has been investi-
gated for the treatment of airway remodeling in COPD. In this 
study, rosuvastatin has been formulated as an NLC dry powder for 
inhalation. The study demonstrated that rosuvastatin NLC success-
fully bypassed the macrophage clearance in vivo, leading to a 
higher concentration of the drug in the lung, highlighting the poten-
tial of the formulation for lung targeting and further for COPD 
treatment [152, 153]. In another in vitro study carried out in a bron-
chial epithelial cell model associated with corticosteroid resistance, 
NLCs containing fluticasone increased the effectiveness of flutica-
sone by improving the corticosteroid mediated effects and de-
creased its side effects [154], which is one of the major problems 
with the existing treatment options [155]. 
 Metal-based complexes have displayed promising activity 
against tuberculosis. Specifically, copper and ruthenium complexes 
have shown excellent antimicrobial potential in tuberculosis. How-
ever, the low solubility of metallic compounds makes their applica-
tion unfeasible. In a study by Sato et al., copper complexes were 
incorporated into the structure of NLCs. This formulation demon-
strated enhanced antimicrobial activity against M. tuberculosis 
[156]. For ruthenium complexes, incorporation into the NLC struc-
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ture resulted in increased bioavailability of ruthenium along with 
reduced toxicity [157]. 
 Rifabutin was studied in another study, where the drug was 
loaded in NCLs for selective delivery to infected alveolar macro-
phages in vitro. This was achieved by two strategies; optimizing 
particle size for macrophage uptake and attachment of mannose 
ligand. The results of this study demonstrated NLCs as a promising 
strategy for the delivery of rifabutin in TB infection [158]. 
12. DENDRIMERS 
 Dendrimers are a family of three-dimensional, nano-sized 
polymers characterized by a compact spherical structure [159]. The 
molecular structure of a dendrimer revolves around a central atom 
or group of atoms known as the core. The branches of other atoms 
called 'dendrons' expand from this central structure through a range 
of chemical reactions. Dendrimers can transport molecules by their 
surface receptors or encapsulate them through cavities between 
their branches [160]. Several in vitro and in vivo studies have used 
dendrimers as carriers to enhance uptake of drugs into cells or syn-
thesized dendrimers with anti-inflammatory properties. 
 Blattes et al., have developed poly-phosphorhydrazone den-
drimers linked with mannose units which mimic M. tuberculosis 
mannose-capped lipoarabinomannan (ManLAMs). ManLAMs in-
hibit the release of proinflammatory cytokines from LPS-induced 
human dendritic cells (DCs). This study demonstrated that different 
dendrimers in terms of size and the number and length of their oli-
gommanoside caps have different potential in reducing TNF-α 
[161].  
 In another in vitro study, mannose coated 5-glycine ethylene 
diamine-polypropylimine (5G EDA–PPI) dendrimer was developed 
as a carrier to transport rifampicin to alveolar macrophages (AM). 
The findings from this study revealed that the retention amount of 
rifampicin in AMs from mannosylated dendrimer formulation was 
significantly higher than the free rifampicin solution [162].  
 Bohr et al. developed two different types of phosphorus-based 
dendrimers (with either pyrrolidinium or morpholinium) to deliver 
small interfering RNA (siRNA) to mouse macrophage cell line 
RAW264.7. Pyrrolidinium dendrimers demonstrated higher anti-
inflammatory properties following stimulation of the macrophages 
with LPS and resulted in a significant reduction in TNF-α expres-
sion. The in vitro anti-inflammatory observations of this study was 
further confirmed in an in vivo murine model of acute lung injury 
[163]. 
 A modified polyamidoamine dendrimer has been used as a vec-
tor to load AS1411 aptamer and short hairpin RNA plasmid in order 
to enhance transfection potential on cancer cells and B-cell lym-
phoma-extra-large (Bcl-xL) protein knockdown. Western blot 
analysis showed a 55% reduction in Bcl-xL protein expression in 
human lung adenocarcinoma cell line (A549), however, this finding 
was not replicated in fibroblasts [164].  
13. QUANTUM DOTS 
 Quantum dots are semiconductor nanocrystals, that exhibit 
unique optical properties for practical applications such as imaging 
and drug delivery. Quantum dots exhibit strong light absorbance, 
bright fluorescence, and photostability [165].  
 Despite the great potential of quantum dots, their clinical appli-
cation and translation have been slow due to the role of heavy met-
als in biological response and induced genotoxicity. The toxic ef-
fects of quantum dots in the respiratory system have been reported 
in vitro and in vivo. Several studies in vitro have reported the reduc-
tion in cell viability, genetic material damage and disordered im-
mune cell reactions, while, in vivo observations include accumula-
tion of quantum dots, lung injury and inflammation [166]. Interest-
ingly, the toxic effects of quantum dots depend on their type, com-
position, dose, size, surface chemistry and structure [167].  
 Recently, a novel formulation of non-cadmium-based quantum 
dots has been developed where no observable toxicity following 
long-term exposure in a murine model was observed, indicating the 
possibility of future clinical applications of quantum dots in the 
treatment of respiratory diseases. The potential role of miRNAs in 
the initiation and progression of lung cancers has been demon-
strated in several studies. These findings have led to the develop-
ment of different detection technologies, including qPCR. In this 
regard, the potential use of quantum dots for cancer cell imaging 
and detection have been highlighted. The large emission spectrum 
and surface chemistry of the quantum dots offer long-term stability 
and a significantly higher sensitivity as bio-probes. Furthermore, as 
mentioned above, recent advances in non-toxic shells and surface 
modification has overcome the toxicity issues and increased the 
ability of quantum dots to quickly identify cancer-associated 
molecular bio-markers [168]. 
14. CARBON NANOTUBES 
 Carbon nanotubes (CNTs) belong to the fullerenes sub-family. 
They are unique sp2-hybridized hydrophobic-tubular structures 
synthesized from carbon allotropes, having a C-C distance of about 
1.4 A˚ with varying diameters from 4 nm to 100 mm [169]. Struc-
turally, these CNTs have exceptionally high drug loading ability, 
high surface area and neutral electrostatic potential, which makes 
them an attractive system for biomedical applications [170, 171]. 
The insoluble nature of these CNTs in aqueous solutions or organic 
solvents and the induction of toxicity by these CNTs in biological 
systems are the foremost challenges that need answers [172]. 
Chemical modification studies have reported a drastic improvement 
in their biocompatibility. This has also reduced the toxicity and 
transformed them into water-soluble nano-systems [173]. Nano-
tubes have a distinct electrical as well as thermal conductivity, and 
mechanical strength, which makes them the nanocarrier of interest 
[174]. 
 Cisplatin (anti-cancerous) was the first drug that was developed 
with single-walled CNTs (SWCNTs) for targeting the cellular re-
ceptor, EGFR. The findings from this study revealed alleviated 
efficiency against squamous tumor cells that showed a high expres-
sion of EGFR [175]. Another study in which functionalized-
SWCNTs were used showed the induction of autophagocytosis in 
both in vitro as well as in vivo conditions by involving Akt/PKB/ 
PI3K signaling pathway in A549 cell lines [176]. Other studies 
using multiwall carbon nanotubes have been found to stimulate 
ROS production via fibrogenic response mediating the NF-kB sig-
naling pathway [177]. Moreover, comparative studies have also 
been conducted on normal and mesothelial cells to understand the 
response of SWCNTs on cell signaling pathways like Akt/PKB/ 
PI3K, MAPK and NF-kB [178]. The findings from various studies 
conducted on targeting the cell signaling pathways have elucidated 
the potential of CNT in treating chronic diseases. These applica-
tions of CNTs expand the horizon of this nano-carrier system and 
directs to explore new potential areas in treating these CRDs by 
targeting potential cell-signaling pathways.  
FUTURE SCOPE AND CONCLUSION 
 Cell signaling pathways have emerged as effective targets for 
treating the CRDs. There is an increasing body of evidence related 
to the inflammatory proteins like COX-2, cPLA2, ICAM, MMP-9, 
and their involvement in the pathophysiology of CRDs like asthma, 
COPD, lung cancer and TB. Additionally, the role and function of 
various cell signaling pathways involving Akt/PKB/ PI3K, JAK-
STAT, MAPK and NF-kB in the regulation of these inflammatory 
proteins, make them possible therapeutic targets. This further 
prompts for the development of new ligands that can serve as ago-
nists or antagonists adaptor molecules for targeting these cell-
signaling pathways and for the treatment of CRDs. Moreover, the 
development of targeted inhibitors with no or minimal side-effects 
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remains to be explored. Although, development of inhibitors for 
targeting cell signaling pathways in the treatment of CRDs seems to 
be an attractive option, nevertheless, it demands an exploration of 
the exact roles of such inflammatory proteins, as well as, the cell 
signaling pathways in these CRDs. Furthermore, appreciating the in 
vivo actions of these drugs and inhibitors in animal models and 
human patients will highlight the real potential, as well as, the effi-
cacy of these drugs in preventing these CRDs. The overall associa-
tions and interactions of these cell signaling pathways with various 
other signaling pathways should be uncovered in future studies. 
LIST OF ABBREVIATIONS 
GPCRs = G Protein-Coupled Receptors 
RTKs = Receptor Tyrosine Kinase 
TGF- β = Transforming Growth Factor- beta 
CRDs = Chronic respiratory diseases 
COPD = Chronic Obstructive Pulmonary Disease 
TB = Tuberculosis 
Akt/PKB/PI3K = Serine/threonine kinase1/protein kinase 
B/phosphoinositide 3-kinase 
JAK-STAT = Janus kinases-signal transducer, and acti-
vator of transcription proteins 
MAPK = Mitogen-activated protein kinase 
NF-κB = Nuclear factor kappa-B 
AHR = Airway hyper-responsiveness 
NSCLC = Non-small cell lung cancer 
SCLC = Small cell lung cancer 
ILD = Interstitial lung disease 
IPF = Idiopathic pulmonary fibrosis 
PIP3 = Phosphatidylinositol-(3,4,5)-trisphosphates 
mTORc2 = Mammalian target of rapamycin complex 
2  
PDK1 = Phosphoinositide-dependent kinase 1 
EGFR = Epidermal growth factor receptor 
PDGFR = Platelet-derived growth factor receptor  
SH2 = Src Homology 2 
ERK = Extracellular-signal regulated kinase 
JNK = c-Jun-N-terminal kinase 
MAPKKs = MAPK kinases 
IL = Interleukin 
PAMPs = Pathogen-associated molecular patterns 
IKKα = Ik kinase alpha 
TLR = Toll like receptors 
Cox-2 = Cyclooxygenase-2 
cPLA2 = Cytosolic phospholipase A2 
ICAM-1 = Intercellular adhesion molecule-1 
MMP-9 = Metalloproteinase-9 
VCAM-1 = Vascular cell adhesion molecule-1 
PKCs = Protein Kinase C 
PIK3CA = Phosphoinositide-3-kinase and catalytic 
alpha polypeptide 
CXCL2/3 = C-X-C motif chemokine ligand 2 
CCL2/5 = C-C Motif Chemokine Ligand 2 
cIAP1 = cellular inhibitor of apoptosis protein 1 
ARDS = Acute respiratory distress syndrome 
PV1 = plasma lemma vesicle-associated protein 
PGE2 = Prostaglandin E2 
NLCs = Nanostructured lipid carriers 
ManLAMs = Mannose-capped lipoarabinomannan 
DCs = dendritic cells 
5G EDA-PPI = 5-glycine ethylene diamine-
polypropylimine 
AMs = alveolar macrophages 
Bcl-xL = B-cell lymphoma-extra-large 
CNTs = Carbon nanotubes 
SWCNTs = Single walled carbon nanotubes 
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